Business
MYND Life Sciences Inc. Has Management CTO Revoked
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - MYND Life Sciences  ( CSE:&#x...
About this update from Mynd Life Sciences Inc
[{"type":"text","content":"MYND Life Sciences Inc. Has Management CTO RevokedVancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) (\"MYND\" or the \"Company\"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease Trade Order. In accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders (\"NP 12-203\") MYND is giving the following update:On March 1, 2023, the Company announced that it applied for a management cease trade order (\"MCTO\") with the applicable securities regulatory authorities in Canada on the basis that the Company would be unable to file its Annual Audited Financial Statement, the Required Filing, for the year ended October 31, 2022 by the applicable filing deadlines. The MCTO was issued on March 1, 2023 and restricted all trading in securities of the Company, whether direct or indirect, by the Chief Executive Officer and Chief Financial Officer of the Company.Mynd is pleased to announce that under section 164 of the Securities Act the MCTO has been revoked upon the filing of all necessary documentation including the Annual Audited Financial Statements and Q1 Financial Statements. Mynd is now up to date on all filings. The Company would like to thank all management for their diligence in achieving this timeline.ABOUT MYND LIFE SCIENCES INC.MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel drug development, diagnostics and vaccines. MYND is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by unique molecular concepts for the applications of psilocybin analogs for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to MYND's mailing list, please visit https://myndsciences.com/contact-us.CONTACT INFORMATIONDr. Lyle Oberg, MD, CEOEmail: [email protected]: www.myndsciences.comForward-Looking StatementsThis news release c...